)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Tessera Defense and Homeland Security
Tessera Defense and Homeland Security (HLSQ) investor relations material
Tessera Defense and Homeland Security Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary8 Oct, 2026
Executive summary
October 7, 2026 employment agreements set compensation for CEO Michael Oster and CFO David Rokach; equity awards are conditional on stockholder approval of an expanded 2026 Equity Incentive Plan.
A Special Meeting is scheduled for October 20, 2026 to consider increasing plan shares from 685,000 to 6,000,000; NYSE American approval to list underlying shares is also required.
Voting matters and shareholder proposals
Stockholders are asked to approve the plan amendment increasing shares reserved for issuance from 685,000 to 6,000,000 at the October 20, 2026 Special Meeting.
The proposed amendment is a condition to Oster's and Rokach's specified equity awards; the awards also require applicable corporate approvals, and listing approval for the underlying shares.
Board of directors and corporate governance
The Compensation Committee and Board approved Oster's and Rokach's agreements on October 7, 2026; each executive is excluded from discussion and voting on approval of his own agreement.
Oster reports to the boards of the parent and Israeli subsidiary; his duties include strategy, risk management, financial reporting, compliance and investor relations.
Rokach serves as CFO, reports to Oster at the subsidiary, and shares board oversight; Oster is also acting Chairman of subsidiary boards.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Tessera Defense and Homeland Security
- CEO and CFO awards hinge on Proposal 1 approval, with additional shares tied to future performance.HLSQ
Proxy filing - Vote centers on a 5.315 million-share plan increase and potential dilution.HLSQProxy filing
- Vote sought to expand equity plan by 5.3M shares to support growth and retention.HLSQProxy filing
- First defense-tech revenue reported post-acquisitions, but liquidity and going concern risks persist.HLSQQ2 2026
- Proxy seeks approval for DFSL acquisition securities, reverse split, and auditor ratification.HLSQProxy filing
- Stockholders to vote on acquisition-related securities issuance, reverse split, and auditor change.HLSQProxy filing
- Shifted to defense/security tech, offering resale shares from acquisitions, with high dilution and financial risk.HLSQRegistration filing
- Merger, $50M financing, and clinical progress drive 2025 milestones amid ongoing losses and delisting risk.HLSQQ2 2024
- BX211 and BX004 show strong efficacy; $12M financing supports key clinical milestones.HLSQQ4 2024 & Study Result
Next Tessera Defense and Homeland Security earnings date
Q3 202613 Nov, 2026
Tessera Defense and Homeland Security
Next Tessera Defense and Homeland Security earnings date
Q3 202613 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
BiomX Inc. is a clinical-stage biotechnology company specializing in the development of both natural and engineered phage therapies. These therapies are designed to target and eliminate specific harmful bacteria, particularly those involved in chronic diseases. The company's key focus areas include conditions like cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX utilizes its proprietary phage technology to discover and validate bacterial targets, subsequently customizing phage compositions to combat these targets effectively. The company is headquartered in Ness Ziona, Israel, and its shares are listed on the NYSE.